| Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates M Saiz-Rodríguez, S Almenara, M Navares-Gómez, D Ochoa, M Román, ... Biomedicines 8 (4), 94, 2020 | 74 | 2020 |
| Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics D Koller, S Almenara, G Mejía, M Saiz-Rodríguez, P Zubiaur, M Román, ... Advances in therapy 38, 1035-1054, 2021 | 29 | 2021 |
| Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability C Espadas, P Ballester, AC Londoño, S Almenara, V Aguilar, C Belda, ... Psychiatry Research 292, 113321, 2020 | 27 | 2020 |
| The effects of Aripiprazole and olanzapine on pupillary light reflex and its relationship with Pharmacogenetics in a randomized Multiple‐Dose trial D Koller, M Saiz‐Rodríguez, P Zubiaur, D Ochoa, S Almenara, M Román, ... British journal of clinical pharmacology 86 (10), 2051-2062, 2020 | 24 | 2020 |
| Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran P Zubiaur, M Saiz-Rodríguez, D Ochoa, M Navares-Gómez, G Mejía, ... Advances in Therapy 37 (8), 3537-3550, 2020 | 22 | 2020 |
| Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis P Gimenez, I Garcia‐Martinez, R Francés, JM Gonzalez‐Navajas, ... Liver International 38 (12), 2219-2227, 2018 | 20 | 2018 |
| Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers P Zubiaur, P Soria-Chacartegui, D Koller, M Navares-Gómez, D Ochoa, ... Biomedicine & Pharmacotherapy 133, 111087, 2021 | 19 | 2021 |
| Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial D Koller, S Almenara, G Mejía, M Saiz‐Rodríguez, P Zubiaur, M Román, ... Human Psychopharmacology: Clinical and Experimental 36 (1), 1-12, 2021 | 12 | 2021 |
| Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines 8 (4): 94 M Saiz-Rodríguez, S Almenara, M Navares-Gómez, D Ochoa, M Román, ... | 9 | 2020 |
| Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers S Almenara, B Lozano, P Gimenez, I Herrera, C Miralles, P Bellot, ... Hepatology International 14, 858-868, 2020 | 6 | 2020 |
| Actual anti-TNF Trough levels relate to serum IL-10 in drug-responding patients with Crohn’s disease P Zapater, S Almenara, A Gutiérrez, L Sempere, M García, R Laveda, ... Inflammatory bowel diseases 25 (8), 1357-1366, 2019 | 5 | 2019 |
| Anaphylaxis probably induced by transfer of amoxicillin via oral sex NG Caballero, S Almenara, AT Terol, JFH de la Parte BMJ Case Reports CP 12 (3), e227398, 2019 | 5 | 2019 |
| The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability P Ballester, C Espadas, AC Londoño, S Almenara, V Aguilar, C Belda, ... Autism Research 15 (1), 192-202, 2022 | 4 | 2022 |
| Pharmacogenetics of pain and analgesia of tapentadol in chronic pain S Almenara, B Planelles, S López-Gil, V López-Gil, MM Inda, A Nuñez, ... BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 119, 33-33, 2016 | 1 | 2016 |
| CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis P Ballester, C Espadas, S Almenara, J Barrachina, J Muriel, E Ramos, ... Pharmaceuticals 16 (7), 954, 2023 | | 2023 |
| Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study S Almenara, B Lozano-Ruiz, I Herrera, P Gimenez, C Miralles, P Bellot, ... Biomedicine & Pharmacotherapy 163, 114885, 2023 | | 2023 |
| Dataset related to article: Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial D Koller, S Almenara, G Mejía, M Saiz-Rodríguez, P Zubiaur, M Román, ... | | 2021 |
| Dataset related to article: Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association … D Koller, S Almenara, G Mejía, M Saiz-Rodríguez, P Zubiaur, M Román, ... | | 2021 |
| Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in healthy volunteers. Association with pharmacogenetics D Koller, S Almenara, G Mejía, M Saiz-Rodríguez, P Zubiaur, M Román, ... bioRxiv, 2020.07. 29.226209, 2020 | | 2020 |
| Effectiveness and analgesic security regarding metabolic profile in non-oncologic chronic pain patients treated with oxycodone A Vara Gonzalez, J Barrachina Bernabeu, J Muriel Serrano, S Almenara, ... BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 123, 34-34, 2018 | | 2018 |
